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FDG-PET-positive lower-extremity sebaceous-gland
carcinoma in a patient with Muir-Torre syndrome
Bina Kviatkovsky, MSc; Elliot Landau, MD; Muhammad Siddique, MBBS; Sami Hossri, MD;
Anoosheh Ebaee, MD; Jean Paul Attalah, MD; Antonio Picon, MD: and Arnold Brenner, DO
Sebaceous-gland carcinoma can occur alone or as one of the defining features of the Muir-Torre syndrome. Cases occurring below the head and neck are extremely rare. Here we describe the case of a 70year-old male with Muir-Torre syndrome who had a recurrent sebaceous-gland carcinoma in the left
lower extremity that demonstrated 18F-FDG avidity. An 18F-FDG-avid lower-extremity sebaceous-gland
carcinoma has not been previously reported.
Background
Sebaceous-gland carcinoma is a rare malignancy. It is
listed as one of the defining features of the Muir-Torre
syndrome (1). Sebaceous-gland carcinoma occurs in the
periocular region in about three quarters of the patients.
The majority of the extraocular cases arise in the head and
neck region. Cases occurring below the head and neck are
extremely rare and tend to have a higher chance of developing visceral malignancies, leading to poorer survival (1).
The majority of the sebaceous-gland carcinoma cases associated with Muir-Torre syndrome actually occur outside the
head and neck region, in most instances involving the torso
and upper extremities (2). Although the FDG-avidity of
sebaceous-gland carcinomas found in the head, neck, and
breast region has been previously identified in case reports,
this phenomenon is yet to be described in the lower
extremity.

Case report
A 70-year-old Caucasian male with a known history of
Muir-Torre syndrome presented with a recurrent lump in
the medial aspect of his left calf. He had previously undergone a resection of sebaceous-gland carcinoma at this site.
Manifestations of Muir-Torre syndrome in his case (besides
the sebaceous-gland carcinoma) included mismatch repairdeficient cancer of the colon and urothelial cancer of the
left renal pelvis, left ureter, and bladder for which he had
undergone left-calf wide local excision, colon resection,
transurethral resection of the bladder tumor, and left
ureteronephrectomy. He reported cancer history in his uncle and father but could not recall the site or type. Medications included lorazepam, bupropion, seroquel, and trazodone for anxiety and depression. He was an ex-heavy
smoker, but denied alcohol abuse or use of recreational
drugs. Vital signs were stable.
The patient presented with a (third) recurrence of the
sebaceous-gland carcinoma in the previously excised location. He was sent for an 18F-FDG PET/CT scan to rule
out new or recurrent visceral malignancies and to assess the
regional nodal status and possibility of distant
metastases. The noncontrast computerized tomographic
(CT) scan demonstrated a 2.9 x 1.8 x 3.7-cm soft-tissue
mass along the medial aspect of the left calf within the
superficial subcutaneous soft tissues (Fig. 1). The 18F-FDG
PET scan revealed intense pathologic uptake (SUVmax
9.1) coregistering with this mass, consistent with biologic
tumor activity. There were no other sites of abnormal 18FFDG uptake (Figs. 2 and 3). The patient underwent a radical excision of the lesion with sentinel lymph node lymphoscintigraphy and biopsy, followed by reconstructive
surgery with placement of a skin graft. Histopathology
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Fig. 1: Lower-extremity noncontrast, low-dose axial CT image of lower extremities demonstrates 2.9 x 1.8 x 3.7-cm
soft-tissue mass along medial aspect of left calf within the
superficial subcutaneous soft tissues. The longest diameter
in the coronal plane is 3.6 cm, in the sagittal plane 3.6 cm,
and in the transaxial 3.2 cm.

Fig. 3: Coregistration of coronal CT Images with 18FDG
PET image. Intense pathological FDG uptake (SUV 9.1) is
present on initial 18FDG PET examination coregistering
with superficial soft-tissue mass, consistent with biologic
tumor activity.

confirmed a sebaceous-gland carcinoma measuring 6.8 x
5.5 x 2.0 cm that was 0.25 mm from the deep (closest) surgical margin. All margins and sentinel lymph nodes proved
negative for carcinoma. The tumor mass was diagnosed as
low-grade sebaceous-gland carcinoma (T2N0). The tumor
was a nonencapsulated, infiltrative neoplasm composed of
atypical epithelial cells with sebaceous differentiation, the
latter with vacuolated cytoplasm and prominent nuclei, and

displayed significant necrosis and mitoses. However, perineural or vascular invasion was not seen (Fig. 4).

Fig. 4: Pathological specimen. A. Well-differentiated sebaceous carcinoma composed of lobules and sheets of tumor
cells with central necrosis (40 X). B. Individual cells have
distinct cell membranes, clear to vacuolated cytoplasm,
vesicular nuclei with prominent nucleoli and mitotic figures
(400X).

About a month after resection, a postoperative irradiation course was directed to the resection site and a small
margin, with a total dose of 50 Gy in 25 treatments using a
prescription isodose line of 90% with a 0.5 cm bolus.
A total-body 18F-FDG PET- CT scan three months
postirradiation did not reveal any residual disease (Fig. 5),
and the patient remains disease-free to date.
Fig. 2: Coregistration of transaxial CT images with 18FDG
PET images. Intense pathological FDG uptake (SUV 9.1) is
present on initial 18FDG PET examination coregistering with
superficial soft-tissue mass, consistent with biologic tumor
activity.
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Discussion
Sebaceous-gland carcinoma is an uncommon and aggressive malignancy (1). The malignant cell of origin is
derived from the adnexal epithelium (1). The etiology of
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head and neck region, mainly in the trunk or upper extremities. However, what is unusual and thus interesting in
our case of sebaceous-gland carcinoma associated with
Muir-Torre syndrome is the involvement of the lower limb.
A literature search found only 24 cases of sebaceous-gland
carcinoma involving the lower extremity, leading to the
conclusion that a primary sebaceous-gland carcinoma in
this region is a novel discovery (1). One case of sebaceousgland carcinoma was reported in the left popliteal fossa (7),
while another manuscript reported sebaceous-gland carcinoma presenting as multiple ulcerated nodules and papules
on the leg of a 32-year-old male (8). Even more interesting
is the fact that none of these 24 cases were described to be
associated with Muir-Torre syndrome.
Another intriguing aspect of this case is the FDG positivity of the lower-extremity sebaceous-gland carcinoma.
18FDG PET/CT has become a significant tool in cancer
imaging for diagnosis, staging, and evaluation of treatment
response. In the case of sebaceous-gland carcinoma, the
rate of nodal and distant metastatic disease approaches
about 25% (9), and thus 18FDG PET/CT may have a potential role in precisely defining the disease stage. However,
as sebaceous-gland carcinoma is rare, there is very limited
literature published on the utility of 18FDG PET/CT in
sebaceous-gland carcinoma, and it is composed only of
case reports that describe a handful of cases. Baek et al.
described 5 cases of periocular sebaceous-gland carcinoma
in which 18FDG PET/CT scan correctly identified 4 of 4
cases of regional lymph-node involvement, whereas 3 of
these 4 were undetected with CT alone (10). Krishna et al.
described two cases of ocular sebaceous-gland carcinoma
that were successfully staged with 18FDG PET/CT (11). In
one case, pathological FDG uptake was noted in submandibular, supraclavicular, mediastinal, and retroperitoneal
lymph nodes (11).
There are even fewer reports describing use of 18FDG
PET/CT in extraocular sebaceous-gland carcinoma.
Bongu et al. described a case of a biopsy-proven recurrent
9-cm sebaceous-gland carcinoma on the back of a 47-yearold male that was intensely FDG-avid, with no other sites
of abnormal 18FDG uptake (12). Until now, only one published report describes a case of an FDG-avid upperextremity sebaceous-gland carcinoma. In this case of a 70year-old female with an enlarging upper-arm sebaceousgland carcinoma, bone scintigraphy demonstrated increased uptake in a large mass in the proximal humerus
with central photopenia. The 18FDG PET/CT scan additionally found distal disease, undetected by other imaging
studies. This included left-lung metastases as well as left
sacroiliac articulation (13).
As up to a third of patients may experience recurrence
post surgery despite excision with clear tumor margins of 5
to 6 mm (14), radiotherapy is often employed, even though
no comparison of postoperative irradiation with surgery
alone has been done (3). We also treated our patient with a
course of postoperative radiotherapy, and he remains without recurrence to date.

Fig. 5. Subsequent coregistered 18FDG PET CT coronal
image post excision and radiotherapy shows no residual
areas of abnormal 18FDG uptake consistent with good
treatment response.

sebaceous-gland carcinoma is not entirely understood. Rare
cases are associated with familial genetic disorders. The
median age at diagnosis is 72, and it is somewhat more
prevalent in Caucasian men (3). Several risk factors for the
development of sebaceous-gland carcinoma have been
proposed in various studies, including radiotherapy in children with retinoblastoma, infection with high-risk human
papilloma virus, and the overexpression of p53 (4). Rare
cases of sebaceous-gland carcinoma are associated with
Muir-Torre syndrome. The diagnostic criterion for MuirTorre syndrome requires the presence of at least one visceral malignancy along with a sebaceous neoplasm (3),
without having an environmental risk factor for sebaceous
neoplasm. Of all sebaceous neoplasms, cutaneous sebaceous adenoma is the one most common encountered in
Muir-Torre syndrome (5). Sebaceous-gland carcinoma is
found only in 23% of cases of Muir-Torre syndrome (14).
The development of sebaceous neoplasms in Muir-Torre
syndrome is related to a defective DNA mismatch-repair
(MMR) system that leads to unchecked genetic aberrations,
including loss of tumor suppressor genes (6). Inactivation of
both alleles of an MMR gene as a result of highly penetrant autosomal dominant mutations, most commonly in
MLH1 and/or MSH2 genes, leads to defective mismatch
repair, resulting in microsatellite instability (MSI). This MSI
can result in frameshift mutations within the microsatellites
containing tumor-suppressor genes (6). These mutations
may interfere with gene-splicing sites, eventually leading to
loss of tumor-suppressor proteins (2).
The MMR status may have a correlation with the site of
development of sebaceous-gland carcinoma. Although the
majority of cases affect the head and neck region, Singh et
al (2), found that 92% of the sebaceous tumors occurring in
MMR-deficient patients, like our patient, occur outside the
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To conclude, a novel presentation of recurring
sebaceous-gland carcinoma of the lower extremity (shown
to be FDG-avid) was seen in a male patient with MuirTorre syndrome. Multiple surgeries and radiotherapy were
required to successfully treat the sebaceous-gland carcinoma as confirmed (post treatment) with 18FDG PET/CT
scan, which demonstrated resolution to a non-18FDG-avid
status. To our knowledge, sebaceous-gland carcinomas have
rarely been reported in the extremities (especially the lower
extremity). Moreover, we present the first case of an
18FDG-avid sebaceous-gland carcinoma of the lower
extremity.
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